In Dublin Smurfit Kappa is buoyed by better-than-expected trading update

What Papa brings to the party is a depth of experience from over 30 years in the business

A look around the world’s stock markets

The prime focus of Valeant was on maximising profit on often older drugs

Aryzta and Valeant chief executives in limelight for differing yet similar reasons

Endo International, another Irish-headquartered specialty drugmaker, fell 23 per cent

Farewell to the Brics, morality and the hedge fund manager and exploiting inattention

Investors can be led astray by firms using non-generally accepted accounting principles

Eye-popping growth and questionable acquisitions raise far too many questions

‘Price-gouging like this . . . is outrageous’ she wrote as drug price rose from $13.50 to $750

Allergan employs about 900 here, most at its manufacturing plant in Westport

Actavis must be getting dizzy from all the approaches

Botox maker’s resistance an unexpected twist for Valeant

Quebec-based pharmaceutical company takes its hostile $50.8 billion bid directly to shareholders

Contact lens maker wants 20 per cent pay cut on top of 200 redundancies

Waterford workers appear to have little leverage in battle to soften swingeing cuts

Multinational has threatened to close Waterford plant if cost-saving measures are not accepted

Scale of cuts savage despite a certain expectation of bad news

TDs complains of little action to generate new employment opportunities

Contact lens maker also seeking 20% pay cuts to bring subsidary in line with other divisions

Increased bid falls short of expectations and stock in both companies falls

Canadian pharma firm teams up with Wall Street hedge fund mogul to mount hostile takeover of Allergan

Cluster of recent deals could each have an impact on Irish drug sector